These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 11994346

  • 1. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height.
    Lazar L, Kauli R, Pertzelan A, Phillip M.
    J Clin Endocrinol Metab; 2002 May; 87(5):2090-4. PubMed ID: 11994346
    [Abstract] [Full Text] [Related]

  • 2. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
    Lazar L, Pertzelan A, Weintrob N, Phillip M, Kauli R.
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
    [Abstract] [Full Text] [Related]

  • 3. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity.
    Lazar L, Padoa A, Phillip M.
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3483-9. PubMed ID: 17579199
    [Abstract] [Full Text] [Related]

  • 4. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM, Pucarelli I, Segni M, Matrunola M, Cerroni F.
    J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
    [Abstract] [Full Text] [Related]

  • 5. Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone.
    Pasquino AM, Pucarelli I, Roggini M, Segni M.
    J Clin Endocrinol Metab; 2000 Feb; 85(2):619-22. PubMed ID: 10690865
    [Abstract] [Full Text] [Related]

  • 6. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function.
    Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R.
    J Clin Endocrinol Metab; 2008 Jan; 93(1):190-5. PubMed ID: 17940112
    [Abstract] [Full Text] [Related]

  • 7. Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method.
    Kauli R, Galatzer A, Kornreich L, Lazar L, Pertzelan A, Laron Z.
    Horm Res; 1997 Jan; 47(2):54-61. PubMed ID: 9030968
    [Abstract] [Full Text] [Related]

  • 8. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R, Soros A, Jakubowicz S.
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [Abstract] [Full Text] [Related]

  • 9. Combined therapy with GnRH analog plus growth hormone in central precocious puberty.
    Pucarelli I, Segni M, Ortore M, Moretti A, Iannaccone R, Pasquino AM.
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():811-20. PubMed ID: 10969926
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty.
    Paterson WF, McNeill E, Young D, Donaldson MD.
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):626-34. PubMed ID: 15521967
    [Abstract] [Full Text] [Related]

  • 15. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation.
    Kamp GA, Mul D, Waelkens JJ, Jansen M, Delemarre-van de Waal HA, Verhoeven-Wind L, Frölich M, Oostdijk W, Wit JM.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2969-75. PubMed ID: 11443153
    [Abstract] [Full Text] [Related]

  • 16. Effect of GnRHa 3.75 mg subcutaneously every 6 weeks on adult height in girls with idiopathic central precocious puberty.
    Liang Y, Wei H, Li J, Hou L, Zhang J, Wu W, Ying Y, Luo X.
    J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):839-46. PubMed ID: 25719299
    [Abstract] [Full Text] [Related]

  • 17. The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: results from a controlled study.
    Saggese G, Federico G, Barsanti S, Fiore L.
    J Clin Endocrinol Metab; 2001 May; 86(5):1900-4. PubMed ID: 11344181
    [Abstract] [Full Text] [Related]

  • 18. Determinants of growth during gonadotropin-releasing hormone analog therapy for precocious puberty.
    Weise M, Flor A, Barnes KM, Cutler GB, Baron J.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):103-7. PubMed ID: 14715835
    [Abstract] [Full Text] [Related]

  • 19. [Effect of gonadotropin-releasing hormone analog combined with stanazolol on final height in girls with idiopathic central precocious puberty and apparent decrease of linear growth].
    Li YH, Zhu SY, Ma HM, Su Z, Chen HS, Chen QL, Gu YF, Du ML.
    Zhonghua Er Ke Za Zhi; 2013 Nov; 51(11):807-12. PubMed ID: 24484553
    [Abstract] [Full Text] [Related]

  • 20. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation.
    Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Mengarda F, Pietrobelli A, Tatò L.
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1096-101. PubMed ID: 12629090
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.